Asset
TEBIPENEM PIVOXIL HYDROBROMIDE
SPERO THERAPEUTICS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04238195 | phase1 | completed | 2020-01-19 | 2020-02-26 | Spero Therapeutics | A Single-Dose, Randomized, Placebo- and Active-Control, Four-Way, Cross-Over Study for the Evaluation of the Effect of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) on the QT/QTc Intervals in Adult Healthy Subjects |
| NCT04376554 | phase1 | completed | 2020-02-10 | 2021-04-06 | Spero Therapeutics | Effect of Tebipenem on Normal Human Intestinal Microbiota |
| NCT04178577 | phase1 | completed | 2019-12-06 | 2020-09-06 | Spero Therapeutics | Phase 1 Study of PK and Safety of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Subjects With Various Degrees Of Renal Function |
| NCT03395249 | phase1 | completed | 2017-10-20 | 2018-08-02 | Spero Therapeutics | Phase 1 Study of Safety, Tolerability and Pharmacokinetics of SPR994 |
| NCT04625855 | phase1 | completed | 2020-09-30 | 2020-10-16 | Spero Therapeutics | Study of the Absorption, Metabolism, and Excretion of [14C]-Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) Following a Single Oral Dose in Healthy Male Subjects |
FDA applications (0)
This company has no applications containing this asset.